| For: | Onoyama T, Takeda Y, Yamashita T, Hamamoto W, Sakamoto Y, Koda H, Kawata S, Matsumoto K, Isomoto H. Programmed cell death-1 inhibitor-related sclerosing cholangitis: A systematic review. World J Gastroenterol 2020; 26(3): 353-365 [PMID: 31988594 DOI: 10.3748/wjg.v26.i3.353] |
|---|---|
| URL: | https://www.wjgnet.com/1007-9327/full/v26/i3/353.htm |
| Number | Citing Articles |
| 1 |
Seita Kataoka, Michihisa Moriguchi, Shinya Okishio, Aya Takahashi, Keiichiro Okuda, Yuya Seko, Atushi Umemura, Kanji Yamaguchi, Aya Miyagawa-Hayashino, Yoshito Itoh. Re-administration of nivolumab after immune checkpoint inhibitor-induced cholangitis: the first reported case. Clinical Journal of Gastroenterology 2022; 15(2) doi: 10.1007/s12328-022-01590-z
|
| 2 |
Mar Riveiro-Barciela, Sabela carballal, Álvaro Díaz-González, Miriam Mañosa, Javier Gallgo-Plazas, Joaquín Cubiella, Paula Jiménez-Fonseca, María Varela, Luis Menchén, Bruno Sangro, Ana Fernández-Montes, Francisco Mesonero, Miguel Ángel Rodríguez-Gandía, Fernando Rivera, María-Carlota Londoño. Management of liver and gastrointestinal toxicity induced by immune checkpoint inhibitors: Position statement of the AEEH-AEG-SEPD-SEOM-GETECCU. Revista Española de Enfermedades Digestivas 2024; doi: 10.17235/reed.2024.10250/2024
|
| 3 |
Sarah L. Zhang, Xiaotang Alison Du, Hanlin L. Wang. Practical Liver Pathology. Practical Anatomic Pathology 2025; doi: 10.1007/978-3-031-97506-6_12
|
| 4 |
Takeshi Tanaka, Arata Sakai, Masahiro Tsujimae, Yasutaka Yamada, Takashi Kobayashi, Atsuhiro Masuda, Yuzo Kodama. Delayed immune-related sclerosing cholangitis after discontinuation of pembrolizumab: A case report. World Journal of Gastroenterology 2022; 28(28): 3732-3738 doi: 10.3748/wjg.v28.i28.3732
|
| 5 |
Masaki Takinami, Akira Ono, Takanori Kawabata, Nobuaki Mamesaya, Haruki Kobayashi, Shota Omori, Kazushige Wakuda, Hirotsugu Kenmotsu, Tateaki Naito, Haruyasu Murakami, Masahiro Endo, Yoshio Kiyohara, Hirofumi Yasui, Masashi Niwakawa, Toshiaki Takahashi. Comparison of clinical features between immune-related sclerosing cholangitis and hepatitis. Investigational New Drugs 2021; 39(6) doi: 10.1007/s10637-021-01136-z
|
| 6 |
Tetsushi Azami, Yuichi Takano, Jun Noda, Masataka Yamawaki, Erika Yoshida, Fumitaka Niiya, Naotaka Maruoka, Takafumi Ogawa, Wataru Ichikawa, Masatsugu Nagahama. Anti programmed death-ligand 1 antibody-related cholangitis without bile duct dilation or stenosis. Clinical Journal of Gastroenterology 2022; 15(4) doi: 10.1007/s12328-022-01651-3
|
| 7 |
Melanie Hundt, Mahmoud Galal Moawad Mohamed, Lily Dara. Reference Module in Biomedical Sciences. 2025; doi: 10.1016/B978-0-323-95488-4.00275-8
|
| 8 |
Benjamin Rabin, Michael Li, Jordan S. Sack, Isaac J. Benque, Stephen D. Zucker. Liver test pattern and histologic bile duct injury do not predict response to treatment of immunotherapy hepatotoxicity. Hepatology Communications 2026; 10(4) doi: 10.1097/HC9.0000000000000922
|
| 9 |
Kenji Urakabe, Takashi Mizushima, Hironobu Tsukamoto, Yasuaki Fujita, Kenichi Haneda, Yuta Suzuki, Akihisa Minowa, Ryo Ishihara, Yusuke Kito, Kazuko Watanabe, Fumihiro Okumura. Two cases of steroid-resistant nivolumab-induced sclerosing cholangitis. Kanzo 2021; 62(11) doi: 10.2957/kanzo.62.712
|
| 10 |
Joseph William Clinton, Sara Kiparizoska, Soorya Aggarwal, Stephanie Woo, William Davis, James H. Lewis. Drug-Induced Liver Injury: Highlights and Controversies in the Recent Literature. Drug Safety 2021; 44(11) doi: 10.1007/s40264-021-01109-4
|
| 11 |
Takanori Ito, Yasuto Takeuchi, Kazuyuki Mizuno, Michitaka Imai, Yoko Yoshimaru, Kazumichi Abe, Masanori Abe, Takanori Matsuura, Masataka Yokode, Masahiro Shiokawa, Yuzo Kodama, Mina Komuta, Kenichi Harada, Atsushi Tanaka. Diagnostic guide for immune checkpoint inhibitor‐induced liver injury. Hepatology Research 2024; 54(8) doi: 10.1111/hepr.14078
|
| 12 |
致文 沈. The Advancement in Diagnosis and Therapy of Liver Injury Induced by Immune Checkpoint Inhibitors. Advances in Clinical Medicine 2021; 11(10) doi: 10.12677/ACM.2021.1110680
|
| 13 |
Nao Takada, Takahiro Fukui, Hidehiro Irie, Yohei Funatsu, Hidefumi Koh. Immune Checkpoint Inhibitor-induced Sclerosing Cholangitis: Three Cases Reported from Our Hospital. Haigan 2024; 64(3) doi: 10.2482/haigan.64.193
|
| 14 |
Zhao Gao, Shikai Wu, Yinmo Yang, Mingxia Sun, Xiaodong Tian, Xuan Jin. Clinical characteristics of liver injury induced by immune checkpoint inhibitors in patients with advanced biliary tract carcinoma. Investigational New Drugs 2023; 41(5) doi: 10.1007/s10637-023-01391-2
|
| 15 |
Shefali Chopra, Samer Gawrieh, Raj Vuppalanchi, Romil Saxena. Role of the Surgical Pathologist in Diagnosis of Drug-induced Liver Injury: Recognizing Specific Patterns of Drug Injury. Advances in Anatomic Pathology 2021; 28(6) doi: 10.1097/PAP.0000000000000307
|
| 16 |
Hao Chi Zhang, Lan Sun Wang, Ethan Miller. Immunotherapy. Advances in Experimental Medicine and Biology 2021; 1342 doi: 10.1007/978-3-030-79308-1_13
|
| 17 |
Ian Liang, Geoffrey Chu, Robert Zielinski. Pembrolizumab Induced Sclerosing Cholangitis: Why You Need a Liver Biopsy. Case Reports in Oncology 2023; doi: 10.1159/000530009
|
| 18 |
Ryunosuke Ooi, Kazunori Tobino, Mitsukuni Sakabe, Takafumi Kawabata, Yuri Hiramatsu, Takuto Sueyasu, Kohei Yoshimine. A case of large-cell lung carcinoma successfully treated with pembrolizumab but complicated with cholangitis. Respiratory Medicine Case Reports 2020; 31 doi: 10.1016/j.rmcr.2020.101197
|
| 19 |
Dimitrios C Ziogas, Helen Gogas. Extending the conversation over the immune-related hepatotoxicity: author response to Dr. Gauci et al
. Journal for ImmunoTherapy of Cancer 2021; 9(3) doi: 10.1136/jitc-2021-002391
|
| 20 |
Evangelos Triantafyllou, Cathrin L. C. Gudd, Lucia A. Possamai. Immune-mediated liver injury from checkpoint inhibitors: mechanisms, clinical characteristics and management. Nature Reviews Gastroenterology & Hepatology 2025; 22(2) doi: 10.1038/s41575-024-01019-7
|
| 21 |
Lorenz Kocheise, Ignazio Piseddu, Joscha Vonderlin, Eric T. Tjwa, Gustav Buescher, Lucy Meunier, Pia Goeggelmann, Francesca Fianchi, Jérôme Dumortier, Mar Riveiro Barciela, Tom J. G. Gevers, Benedetta Terziroli Beretta-Piccoli, Maria-Carlota Londoño, Sona Frankova, Thomas Roesner, Vincent Joerg, Constantin Schmidt, Fabian Glaser, Jan P. Sutter, Thorben W. Fründt, Ansgar W. Lohse, Samuel Huber, Johann von Felden, Marcial Sebode, Kornelius Schulze. PD-1/PD-L1 immune checkpoint therapy demonstrates favorable safety profile in patients with autoimmune and cholestatic liver disease. Frontiers in Immunology 2024; 14 doi: 10.3389/fimmu.2023.1326078
|
| 22 |
Donna Zhuang, David Zhang, Stephen Riordan. Hepatobiliary complications of immune checkpoint inhibitors in cancer. Exploration of Targeted Anti-tumor Therapy 2024; 5(4) doi: 10.37349/etat.2024.00257
|
| 23 |
Babina Gosangi, Lacey McIntosh, Abhishek Keraliya, David Victor Kumar Irugu, Akshay Baheti, Ashish Khandelwal, Richard Thomas, Marta Braschi-Amirfarzan. Imaging features of toxicities associated with immune checkpoint inhibitors. European Journal of Radiology Open 2022; 9 doi: 10.1016/j.ejro.2022.100434
|
| 24 |
Rohit Agrawal, Grace Guzman, Saman Karimi, Pier Cristoforo Giulianotti, Alfredo Jose Mena Lora, Shikha Jain, Meshaal Khan, Brian R Boulay, Yolande Chen. Immunoglobulin G4 associated autoimmune cholangitis and pancreatitis following the administration of nivolumab: A case report. World Journal of Clinical Cases 2022; 10(20): 7124-7129 doi: 10.12998/wjcc.v10.i20.7124
|
| 25 |
Shusaku Honma, Satoshi Watanabe, Sanae Nakajima. Pembrolizumab-Related Sclerosing Cholangitis in a Patient With High Microsatellite Instability Gastric Cancer: A Case Report. Cureus 2024; doi: 10.7759/cureus.66425
|
| 26 |
Randy Adiwinata, Caroline Tanadi, Fegita Pajala, Kevin Tandarto, Maureen Stella, Jeffry Tenggara, Ralph Gunarsa, Paulus Simadibrata, Lianda Siregar, Saut Nababan, Budiman Sulaiman, Irsan Hasan, Cosmas Lesmana, Aru Sudoyo. Immune Checkpoint Inhibitor-induced Hepatitis, an Emerging Issue in Precision Cancer Therapy Era: A Narrative Literature Review. Rambam Maimonides Medical Journal 2026; 17(1) doi: 10.5041/RMMJ.10571
|
| 27 |
Kefan Chen, Junhao He, Jing Xu, Jie Chen. Effectiveness of immunosuppressant use for the treatment of immune checkpoint inhibitor-induced liver injury: A systematic review and meta-analysis. Frontiers in Oncology 2023; 13 doi: 10.3389/fonc.2023.1088741
|
| 28 |
Tess McClure, Wanyuan Cui, Khashayar Asadi, Thomas John, Adam Testro. Case of nivolumab-induced sclerosing cholangitis: lessons from long-term follow-up. BMJ Open Gastroenterology 2020; 7(1) doi: 10.1136/bmjgast-2020-000487
|
| 29 |
Hao Chi Zhang, Lan Sun Wang, Ethan Miller. Managing Immunotherapy Related Organ Toxicities. 2022; doi: 10.1007/978-3-031-00241-0_7
|
| 30 |
Takayuki Yamamoto, Yukihiro Sugimoto, Ryouta Aoki, Kunihiro Kudou, Hirofumi Nakano, Teruo Nakaya, Mio Nakazato, Masanori Takayama. A Case of Pembrolizumab-related Sclerosing Cholangitis Successfully Treated with Prednisolone. Haigan 2021; 61(7) doi: 10.2482/haigan.61.951
|
| 31 |
Kana Kawata, Dai Inoue, Takahiro Komori, Takashi Matsubara, Fumihito Toshima, Kazuto Kozaka, Masahiro Yanagi, Hiroko Ikeda, Satoshi Kobayashi. Case of simultaneous occurrence of hepatitis, cholangitis, and pancreatitis as immune-related adverse events induced by immune checkpoint inhibitor therapy: a case report. Abdominal Radiology 2025; 50(12) doi: 10.1007/s00261-025-04994-w
|
| 32 |
Borui Pi, Jin Wang, Yifan Tong, Qiao Yang, Fangfang Lv, Yunsong Yu. Immune-related cholangitis induced by immune checkpoint inhibitors: a systematic review of clinical features and management. European Journal of Gastroenterology & Hepatology 2021; 33(1S) doi: 10.1097/MEG.0000000000002280
|
| 33 |
Noriaki Iijima, Yasutaka Ishii, Shinya Nakamura, Juri Ikemoto, Masaru Furukawa, Yumiko Yamashita, Risa Nomura, Shin Ohtagaki, Yoshihiro Tanaka, Morihito Okada, Noboru Hattori, Sachio Takeno, Nobuyuki Hinata, Akio Tanaka, Wataru Okamoto, Hideki Ohdan, Souichi Yanamoto, Tomonao Aikawa, Ken Yamaguchi, Shinya Takahashi, Tatsuo Ichinohe, Yuji Murakami, Masataka Tsuge, Shiro Oka. Clinical Characteristics and Predictive Factors of Immune-Mediated Cholangitis: A Large Single-Center Retrospective Observational Study. Cancers 2026; 18(4) doi: 10.3390/cancers18040685
|
| 34 |
Jarrett Rong, Faraz Jafri, Sean Ngo, Anirudha Chatterjee, Maria Julia Moura Nascimento Santos, Devin Garza, Hamza Salim, Raakhi Menon, Rachel Mortan, Andres Caleb Urias Rivera, Hao Chi Zhang, Anisha Patel, Cristhiam Rojas Hernandez, Yuanteng Jeff Li, Ajay Sheshadri, Ashley Aaroe, Afreen Shariff, Bryan Schneider, Anusha Thomas, Yinghong Wang. Rare irAEs associated with immune checkpoint inhibitor therapy. Expert Opinion on Drug Safety 2026; 25(8) doi: 10.1080/14740338.2026.2629998
|
| 35 |
Takato Maeda, Masaki Munakata, Hiroshi Numao, Norihiro Hanabata, Koji Shimaya, Shohei Igarashi, Masayoshi Ko, Yukari Fukutoku, Ryoichi Kikuchi, Hirotake Sakuraba. Delayed and multisystem immune-related adverse events in MSI-high colon cancer treated with nivolumab plus ipilimumab. Clinical Journal of Gastroenterology 2026; doi: 10.1007/s12328-026-02460-8
|
| 36 |
Nur Aisyah Muhd Opandi, Aqeel Ahmed, Emma Robinson, Answar Abdulrehman. Pembrolizumab-Induced Secondary Cholangitis: A Case Report. Cureus 2025; doi: 10.7759/cureus.98586
|
| 37 |
Mar Riveiro-Barciela, Sabela Carballal, Álvaro Díaz-González, Míriam Mañosa, Javier Gallego-Plazas, Joaquín Cubiella, Paula Jiménez-Fonseca, María Varela, Luis Menchén, Bruno Sangro, Ana Fernández-Montes, Francisco Mesonero, Miguel Ángel Rodríguez-Gandía, Fernando Rivera, María-Carlota Londoño. Management of liver and gastrointestinal toxicity induced by immune checkpoint inhibitors: Position statement of the AEEH–AEG–SEPD–SEOM–GETECCU. Gastroenterología y Hepatología (English Edition) 2024; 47(4) doi: 10.1016/j.gastre.2023.10.003
|
| 38 |
Yuchen Li, Lori Stewart, Shangguo Tang, Elaine McWhirter. Pembrolizumab-induced immune-related sclerosing cholangitis. BMJ Case Reports 2023; 16(11) doi: 10.1136/bcr-2023-256125
|
| 39 |
Takanori Ito, Yasuto Takeuchi, Kazuyuki Mizuno, Michitaka Imai, Yoko Yoshimaru, Kazumichi Abe, Masanori Abe, Takanori Matsuura, Masataka Yokode, Masahiro Shiokawa, Yuzo Kodama, Mina Komuta, Kenichi Harada, Atsushi Tanaka. Guide for the Diagnosis of Immune Checkpoint Inhibitor-Induced Liver Injury. Kanzo 2024; 65(6) doi: 10.2957/kanzo.65.268
|
| 40 |
Takanori Ito, Yasuto Takeuchi, Kazuyuki Mizuno, Michitaka Imai, Yoko Yoshimaru, Kazumichi Abe, Masanori Abe, Takanori Matsuura, Masataka Yokode, Masahiro Shiokawa, Sadahisa Ogasawara, Yuzo Kodama, Mina Komuta, Kenichi Harada, Naoya Sakamoto, Atsushi Tanaka. A Guide for the Diagnosis and Treatment of Immune Checkpoint Inhibitor-Induced Liver Injury. Kanzo 2025; 66(9) doi: 10.2957/kanzo.66.375
|
| 41 |
Sanja Stojsavljevic Shapeski, Goran Poropat, Iva Skocilic, Petra Puz Britvic, Juraj Prejac, Alojzije Lackovic, Lucija Virovic Jukic, Tajana Filipec Kanizaj, Tajana Pavic, Maja Mijic, Ivica Grgurevic, Tomislav Bokun, Sandra Milic, Milos Lalovac, Anita Skrtic, Petra Dinjar Kujundzic, Ana Ostojic, Frane Pastrovic, Jasna Radić, Dorotea Bozic, Bruno Buric, Marin Golcic, Laura Rados, Sara Matulic, Ema Somen, Neven Ljubicic, Josipa Bilandzic, Maja Kolak, Ana-Marija Bukovica Petrc, Lana Bolf, Sanja Ropac, Vlasta Orlic Karbic, Dragan Trivanovic, Iris Vuković, Ivana Mikolasevic. Hepatic and Pancreatobiliary Immune-Related Adverse Events in Patients Receiving Immune Checkpoint Inhibitors: A Multidisciplinary Approach. Biomedicines 2026; 14(9) doi: 10.3390/biomedicines14091964
|
| 42 |
Sachiko Matsumoto, Keisuke Watanabe, Nobuaki Kobayashi, Kuniyasu Irie, Shoji Yamanaka, Takeshi Kaneko. Pembrolizumab‐induced secondary sclerosing cholangitis in a non‐small cell lung cancer patient. Respirology Case Reports 2020; 8(5) doi: 10.1002/rcr2.560
|
| 43 |
Obada Daaboul, Genan Arman, Mulham Alom, Aman Swied. Diagnostic Dilemma: Metastatic Breast Adenocarcinoma Presenting With a Cholestatic Liver Injury Without Radiological Findings of Liver Metastases. Cureus 2025; doi: 10.7759/cureus.81368
|
| 44 |
Hao Chi Zhang, Andres Urias Rivera, Ethan Miller, Yun Shin Chun, Celia Robinson Ledet, Lan Wang. Challenging Cases in Immunotherapy Related Organ Toxicities. 2025; doi: 10.1007/978-3-031-83533-9_34
|
| 45 |
Anqi Lin, Qiliang Huang, Jian Zhang, Peng Luo. Digestive System Toxicities of Immune Checkpoint Inhibitors: Mechanisms and Clinical Implications. BIO Integration 2026; 7(1) doi: 10.15212/bioi-2025-0169
|
| 46 |
Kotoba Esaki, Hideyuki Horikoshi, Maiko Awashima, Satoshi Nakayama, Yoshiko Kichikawa. Optimal Corticosteroid Therapy Based on Liver Biopsy for Severe Immune-Mediated Hepatitis During Pembrolizumab Treatment: A Case Report. Cureus 2026; doi: 10.7759/cureus.104904
|
| 47 |
Fernando Bessone, Einar Stefan Bjornsson. Checkpoint inhibitor-induced hepatotoxicity: Role of liver biopsy and management approach. World Journal of Hepatology 2022; 14(7): 1269-1276 doi: 10.4254/wjh.v14.i7.1269
|
| 48 |
Haowen Tan, Xuan Ou, Ying Chen, Weiwei Lan, Luping Luo. A Pharmacovigilance Study of Immune Checkpoint Inhibitor‐Associated Cholangitis: Insights From the FDA Adverse Event Reporting System. Hepatology Research 2026; 56(4) doi: 10.1111/hepr.70082
|
| 49 |
Fernando Bessone, Einar S. Björnsson. Drug-Induced Liver Injury due to Biologics and Immune Check Point Inhibitors. Medical Clinics of North America 2023; 107(3) doi: 10.1016/j.mcna.2022.12.008
|
| 50 |
J. McKenzie, E. Sneath, A. Trinh, M. Nolan, L. Spain. Updates in the pathogenesis and management of immune-related enterocolitis, hepatitis and cardiovascular toxicities. Immuno-Oncology and Technology 2024; 21 doi: 10.1016/j.iotech.2024.100704
|
| 51 |
Maohe Yu, Hao Wang, Lve Cheng, Xinlang Wu, Qujin Li, Junwei Niu, Haowen Li, Shengwei Li. Integrated pharmacovigilance assessment of drug-associated cholangitis: signal detection, clinical characterization, and mechanistic insights. Frontiers in Pharmacology 2026; 17 doi: 10.3389/fphar.2026.1891926
|
| 52 |
Julie R Brahmer, Hamzah Abu-Sbeih, Paolo Antonio Ascierto, Jill Brufsky, Laura C Cappelli, Frank B Cortazar, David E Gerber, Lamya Hamad, Eric Hansen, Douglas B Johnson, Mario E Lacouture, Gregory A Masters, Jarushka Naidoo, Michele Nanni, Miguel-Angel Perales, Igor Puzanov, Bianca D Santomasso, Satish P Shanbhag, Rajeev Sharma, Dimitra Skondra, Jeffrey A Sosman, Michelle Turner, Marc S Ernstoff. Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immune checkpoint inhibitor-related adverse events. Journal for ImmunoTherapy of Cancer 2021; 9(6) doi: 10.1136/jitc-2021-002435
|
| 53 |
Zhao Gao, Ji-Xin Zhang, Xiao-Dong Tian, Shi-Kai Wu, Xuan Jin. Rapid cholestasis improvement as key strategy for steroid-refractory immune-related cholangitis: A case report. World Journal of Gastrointestinal Oncology 2025; 17(9): 108960 doi: 10.4251/wjgo.v17.i9.108960
|
| 54 |
Mayuko Kondo, Keisuke Ojiro, Makoto Ueno, Yukie Nakadai, Takaya Tabuchi, Ryosuke Kasuga, Hitomi Hoshi, Akihiro Yamaguchi, Chu Po-sung, Nobuhito Taniki, Shingo Usui, Takanori Kanai, Nobuhiro Nakamoto. Early steroid initiation may improve outcomes in immune checkpoint inhibitor-related cholangitis: a multicenter cohort study. Immunological Medicine 2026; doi: 10.1080/25785826.2026.2699469
|
| 55 |
Marie-Léa Gauci, Barouyr Baroudjian, Celeste Lebbe, Olivier Roux. When steroids are not enough in immune-related hepatitis: current clinical challenges discussed on the basis of a case report. Journal for ImmunoTherapy of Cancer 2021; 9(3) doi: 10.1136/jitc-2021-002337
|
| 56 |
Shin Satake, Naruyasu Kakita, Hiroshi Tsumuro, Midori Jono, Toshimitsu Yasui, Kazuhiro Katayama. Concurrent Immune-Related Polyarthritis and Hyperbilirubinemia during Atezolizumab Plus Bevacizumab Therapy for Hepatocellular Carcinoma: A Steroid-Responsive Case. Kanzo 2026; 67(3) doi: 10.2957/kanzo.67.233
|
| 57 |
Rui Jiao, Chenyu Wang, Hongyan Ying, Muwen Nie, Jing Leng, Yuan Liu, Zhiyang Zhang, Na Zhou, Chunmei Bai. Case report of immune checkpoint inhibitor induced cholestatic hepatitis, acute renal injury and asymptomatic pancreatic enzyme elevation simultaneously. Frontiers in Immunology 2025; 16 doi: 10.3389/fimmu.2025.1679328
|
| 58 |
Einar S. Björnsson, Raul J. Andrade. Long-term sequelae of drug-induced liver injury. Journal of Hepatology 2022; 76(2) doi: 10.1016/j.jhep.2021.10.011
|
| 59 |
Lily Dara, Eleonora De Martin. Immune‐Mediated Liver Injury From Checkpoint Inhibitor: An Evolving Frontier With Emerging Challenges. Liver International 2025; 45(2) doi: 10.1111/liv.16198
|
| 60 |
Sean Ngo, Jarrett Rong, Raakhi Menon, Carolina Colli Cruz, Anirudha Chatterjee, Rachel Mortan, Hamza Salim, Andres Urias Rivera, Faraz I. Jafri, Devin Garza, Stephanie Kim, Pauline Funchain, Hao Chi Zhang, Ajay Sheshadri, Marc Ernstoff, Tomas Neilan, Thein Hlaing Oo, Eric Roeland, Ata Moshiri, Yinghong Wang. Chronic sequelae of immune-related adverse events. Expert Opinion on Drug Safety 2026; 25(8) doi: 10.1080/14740338.2026.2635994
|
| 61 |
Yuki Yoshikawa, Michio Imamura, Kenji Yamaoka, Yumi Kosaka, Eisuke Murakami, Kei Morio, Hatsue Fujino, Takashi Nakahara, Wataru Okamoto, Masami Yamauchi, Tomokazu Kawaoka, Masataka Tsuge, Akira Hiramatsu, Clair Nelson Hayes, Hiroshi Aikata, Kazunori Fujitaka, Kouji Arihiro, Noboru Hattori, Kazuaki Chayama. A case with life-threatening secondary sclerosing cholangitis caused by nivolumab. Clinical Journal of Gastroenterology 2021; 14(1) doi: 10.1007/s12328-020-01287-1
|
| 62 |
Brian H. Horwich, Douglas T. Dieterich. Phenotypes of Primary Sclerosing Cholangitis and Differential Diagnosis. Clinics in Liver Disease 2024; 28(1) doi: 10.1016/j.cld.2023.07.006
|
| 63 |
Emanuel Raschi, Milo Gatti, Francesco Gelsomino, Andrea Ardizzoni, Elisabetta Poluzzi, Fabrizio De Ponti. Lessons to be Learnt from Real-World Studies on Immune-Related Adverse Events with Checkpoint Inhibitors: A Clinical Perspective from Pharmacovigilance. Targeted Oncology 2020; 15(4) doi: 10.1007/s11523-020-00738-6
|
| 64 |
Lina Hountondji, Christophe Ferreira De Matos, Fanny Lebossé, Xavier Quantin, Candice Lesage, Pascale Palassin, Valérian Rivet, Stéphanie Faure, Georges-Philippe Pageaux, Éric Assenat, Laurent Alric, Amel Zahhaf, Dominique Larrey, Philine Witkowski Durand Viel, Benjamin Riviere, Selves Janick, Stéphane Dalle, Alexandre Thibault Jacques Maria, Thibaut Comont, Lucy Meunier. Clinical pattern of checkpoint inhibitor-induced liver injury in a multicentre cohort. JHEP Reports 2023; 5(6) doi: 10.1016/j.jhepr.2023.100719
|
| 65 |
Tsukasa Yasuda, Takanori Ito, Takuya Ishikawa, Kazuyuki Mizuno, Takafumi Yamamoto, Shinya Yokoyama, Kenta Yamamoto, Norihiro Imai, Yoji Ishizu, Takashi Honda, Yuichi Koshiyama, Satoshi Yasuda, Hidenori Toyoda, Yuichi Ando, Yoshie Shimoyama, Hiroki Kawashima. Clinical features and pathological findings by liver biopsy in patients with immune-related sclerosing cholangitis induced by immune checkpoint inhibitors. Digestive and Liver Disease 2025; 57(4) doi: 10.1016/j.dld.2025.01.037
|
| 66 |
Lucy Meunier, David E. Kleiner, Benjamin Riviere, Huiman Barnhart, Ronald Kamusiime, Vincent L. Chen, Dominique Larrey, Robert J. Fontana. Liver biopsy findings and clinical correlates in immune-mediated liver injury from checkpoint inhibitors. Hepatology Communications 2026; 10(8) doi: 10.1097/HC9.0000000000000988
|
| 67 |
Akihiro Tsukaguchi, Norihiko Yamaguchi, Hiroyuki Ogawa, Toshiyuki Ikeda. Concurrent Nivolumab-Induced Gastritis and Cholangitis Accompanied by Biliary Tract Hemorrhage in a Patient With Stage IV Lung Adenocarcinoma. Cureus 2023; doi: 10.7759/cureus.46392
|
| 68 |
Takafumi Yamamoto, Kazuyuki Mizuno, Takanori Ito, Shinya Yokoyama, Kenta Yamamoto, Norihiro Imai, Yoji Ishizu, Takashi Honda, Takuya Ishikawa, Akira Kanamori, Satoshi Yasuda, Hidenori Toyoda, Kenji Yokota, Tetsunari Hase, Naoki Nishio, Osamu Maeda, Makoto Ishii, Michihiko Sone, Yuichi Ando, Masashi Akiyama, Masatoshi Ishigami, Hiroki Kawashima. Abdominal pain accompanied by elevated serum inflammatory markers and biliary enzymes for diagnosing immune checkpoint inhibitor-induced sclerosing cholangitis. Investigational New Drugs 2023; 41(3) doi: 10.1007/s10637-023-01366-3
|
| 69 |
Chihiro Sumi, Masayo Yamamoto, Rena Sasaki, Takuya Funayama, Takeshi Saito, Mayumi Hatayama, Motohiro Shindo, Yasuhiro Umekage, Takaaki Sasaki, Sayaka Yuzawa, Mishie Tanino, Shuichiro Takahashi. Successful Treatment of Aplastic Anemia Induced by Immune Checkpoint Inhibitors for Lung Cancer. Internal Medicine 2026; 65(4) doi: 10.2169/internalmedicine.5590-25
|
| 70 |
Mar Riveiro-Barciela, Sabela Carballal, Álvaro Díaz-González, Míriam Mañosa, Javier Gallego-Plazas, Joaquín Cubiella, Paula Jiménez-Fonseca, María Varela, Luis Menchén, Bruno Sangro, Ana Fernández-Montes, Francisco Mesonero, Miguel Ángel Rodríguez-Gandía, Fernando Rivera, María-Carlota Londoño. Management of liver and gastrointestinal toxicity induced by immune checkpoint inhibitors: Position statement of the AEEH–AEG–SEPD–SEOM–GETECCU. Gastroenterología y Hepatología 2024; 47(4) doi: 10.1016/j.gastrohep.2023.10.009
|
| 71 |
Shinji Nabeshima, Masahiro Yamasaki, Naoko Matsumoto, Shintaro Takaki, Yumi Nishi, Kazuma Kawamoto, Masaya Taniwaki, Nobuyuki Ohashi, Noboru Hattori. Atezolizumab-induced Sclerosing Cholangitis in a patient with lung cancer: A case report. Cancer Treatment and Research Communications 2021; 26 doi: 10.1016/j.ctarc.2020.100270
|
| 72 |
Daniel R. Ludwig, Mark A. Anderson, Malak Itani, Kedar G. Sharbidre, Neeraj Lalwani, Raj M. Paspulati. Secondary sclerosing cholangitis: mimics of primary sclerosing cholangitis. Abdominal Radiology 2022; 48(1) doi: 10.1007/s00261-022-03551-z
|
| 73 |
Joshua Newington, Daniel Patterson, Pilar Sanchez. Delayed onset autoimmune cholangitis in a patient treated with pembrolizumab. BJR|Case Reports 2024; 10(6) doi: 10.1093/bjrcr/uaae040
|
| 74 |
Johanna Winter, Max M. Lenders, Maximilian Gassenmaier, Andrea Forschner, Ulrike Leiter, Benjamin Weide, Mette-Triin Purde, Lukas Flatz, Antonio Cozzio, Martin Röcken, Claus Garbe, Thomas K. Eigentler, Nikolaus B. Wagner. Prognostic role of gamma-glutamyl transferase in metastatic melanoma patients treated with immune checkpoint inhibitors. Cancer Immunology, Immunotherapy 2021; 70(4) doi: 10.1007/s00262-020-02768-5
|
| 75 |
Inês Soldin, Raquel Teixeira, Raquel Ortigão, Alexandra Lapa, Sérgio Lima. Immune Checkpoint Inhibitor-Induced Hepatitis: A Case Report of Challenging Management. Cureus 2025; doi: 10.7759/cureus.77331
|
| 76 |
Yoshiya Takeda, Osamu Inatomi, Shuhei Shintani, Takehide Fujimoto, Atsushi Nishida, Hiromu Kutsumi, Akira Andoh. Clinical response in the haustra-like folds observed during peroral cholangioscopy following steroid therapy for immune checkpoint inhibitor-induced cholangitis. Endoscopy 2022; 54(S 02) doi: 10.1055/a-1899-8619
|
| 77 |
Edmond Atallah, Sreelakshmi Kotha, Philip Berry, Yoh Zen, Alyn L Cratchley, Deepak Joshi, Chenchu R Chimakurthi. Checkpoint inhibitor-induced cholangiopathy. Frontline Gastroenterology 2025; doi: 10.1136/flgastro-2024-103050
|
| 78 |
Zheqing Liu, Xiaojing Du, Meiling Deng, Yuanyuan Chen, Shaoxiong Wu. Successful replacement for recurrent nasopharyngeal carcinoma with cholecystitis induced by PD-1 antibody: a case report. Immunotherapy 2024; 16(14-15) doi: 10.1080/1750743X.2024.2382670
|
| 79 |
Einar S. Bjornsson, Daiana Arnedillo, Fernando Bessone. Secondary Sclerosing Cholangitis due to Drugs With a Special Emphasis on Checkpoint Inhibitors. Liver International 2025; 45(4) doi: 10.1111/liv.16163
|
| 80 |
Robert J. Fontana, Yi-Ju Li, Vincent Chen, David Kleiner, Andrew Stolz, Joe Odin, Raj Vuppalanchi, Jiezhun Gu, Lily Dara, Huiman Barnhart. Genetic variants associated with immune-mediated liver injury from checkpoint inhibitors. Hepatology Communications 2024; 8(9) doi: 10.1097/HC9.0000000000000518
|
| 81 |
Sam Talbot, Vivienne MacLaren, Heather Lafferty. Sclerosing cholangitis in a patient treated with nivolumab. BMJ Case Reports 2021; 14(5) doi: 10.1136/bcr-2021-241700
|
| 82 |
Yanmei Yang, Yongjin He, Ping Zhang, Chunyan Wang. Key developments and hotspots in programmed cell death in liver cancer pain: a bibliometric study. Discover Oncology 2025; 16(1) doi: 10.1007/s12672-025-02759-x
|
| 83 |
V. T. Ivashkin, О. M. Drapkina, K. L. Raikhelson, S. V. Okovityi, M. V. Maevskaya, V. R. Grechishnikova, M. S. Zharkova, O. V. Khlynova, O. А. Gladkov, T. A. Deeva, S. A. Alekseenko, V. A. Akhmedov, I. G. Bakulin, N. V. Bakulina, A. Yu. Baranovsky, L. G. Vologzhanina, E. V. Golovanova, D. V. Glushenkov, A. I. Dolgushina, O. A. Igumnova, K. V. Ivashkin, I. V. Kozlova, E. A. Kondrashina, L. B. Lazebnik, I. V. Maev, N. V. Marchenko, M. Yu. Nadinskaia, A. V. Novik, M. F. Osipenko, E. V. Pazenko, I. Yu. Pirogova, M. K. Prashnova, V. A. Prikhodko, A. A. Saenko, L. V. Tarasova, T. A. Tikhonova, P. E. Tkachenko, I. B. Khlynov, Yu. V. Tsyganova. Clinical Guidelines of the Russian Society for the Study of the Liver, Russian Gastroenterological Association, Russian Society for the Prevention of Non-Communicable Diseases, Russian Association of Endocrinologists, Russian Scientific Medical Society of Therapists, National Society of Preventive Cardiology, Russian Association of Gerontologists and Geriatricians on Drug-Induced Liver Injury. Russian Journal of Gastroenterology, Hepatology, Coloproctology 2026; 36(1) doi: 10.22416/1382-4376-2026-36-1-70-146
|
| 84 |
Jean-Yves Scoazec. Drug-induced bile duct injury: new agents, new mechanisms. Current Opinion in Gastroenterology 2022; 38(2) doi: 10.1097/MOG.0000000000000813
|
| 85 |
Lucy Meunier, Lina Hountondji, Hélène Jantzem, Jean Luc Faillie, Alexandre Maria, Pascale Palassin, Stéphanie Faure, Philine Witkowski-Durand-Viel, Xavier Quantin, Georges Philippe Pageaux. Cholangitis Induced by Immune Checkpoint Inhibitors: Analysis of Pharmacovigilance Data. Clinical Gastroenterology and Hepatology 2024; 22(7) doi: 10.1016/j.cgh.2023.12.008
|
| 86 |
Mauro Cataldi, Federica Manco, Giovanni Tarantino. Steatosis, Steatohepatitis and Cancer Immunotherapy: An Intricate Story. International Journal of Molecular Sciences 2021; 22(23) doi: 10.3390/ijms222312947
|
| 87 |
Leilei Ai, Jian Chen, Hao Yan, Qiaojun He, Peihua Luo, Zhifei Xu, Xiaochun Yang. <p>Research Status and Outlook of PD-1/PD-L1 Inhibitors for Cancer Therapy</p>. Drug Design, Development and Therapy 2020; doi: 10.2147/DDDT.S267433
|
| 88 |
An-Tian Chen, Yue-Quan Shi, Bei Tan, Liang Zhu, Ya-Ping Luo, Wei Zhong, Meng-Zhao Wang, Yan Xu. Case Report: A Programmed Cell Death-1 Inhibitor-Related Abdominal Fibroinflammatory Reaction Affecting Multiple Organs in A Non-Small-Cell Lung Cancer Patient. Frontiers in Immunology 2022; 13 doi: 10.3389/fimmu.2022.874932
|
| 89 |
Takafumi Yamamoto, Takanori Ito, Kazuyuki Mizuno, Yokoyama Shinya, Kenta Yamamoto, Norihiro Imai, Yoji Ishizu, Takashi Honda, Hiroki Kawashima, Toshinori Matsui, Tetsunari Hase, Naozumi Hashimoto, Masatoshi Ishigami. A case of antiprogrammed death‐ligand 1 antibody‐induced multisystem immune‐related adverse events with pancreatitis and steroid‐resistant sclerosing cholangitis. Journal of Digestive Diseases 2022; 23(7) doi: 10.1111/1751-2980.13122
|
| 90 |
Maria Julia Moura, Anirudha Chatterjee, Sharada Wali, Devin R. Garza, Hamza Salim, Jarrett Rong, Raakhi Menon, Faraz Jafri, Andres Urias Rivera, Rachel Mortan, Nicolas L. Palaskas, Kerry L. Reynolds, Rebecca K. Leaf, Nupur Kikani, Anusha Thomas, Hao Chi Zhang, Lan Sun Wang, Sudhakar Tummala, Nagham Al-Zubidi, Ajay Sheshadri, Ala Abudayyeh, Yuanteng Li Jeff, Yinghong Wang. Refractory immune-related adverse events (irAEs) associated with immune checkpoint inhibitor therapy: a multiorgan management review. Expert Opinion on Drug Safety 2026; doi: 10.1080/14740338.2026.2659253
|
| 91 |
Kentaro Sato, Manabu Hayashi, Kazumichi Abe, Masashi Fujita, Atsushi Takahashi, Hiromasa Ohira. Pembrolizumab-induced sclerosing cholangitis in a lung adenocarcinoma patient with a remarkable response to chemotherapy: a case report. Clinical Journal of Gastroenterology 2020; 13(6) doi: 10.1007/s12328-020-01178-5
|
| 92 |
Takanori Ito, Kazuyuki Mizuno, Takafumi Yamamoto, Tsukasa Yasuda, Shinya Yokoyama, Kenta Yamamoto, Norihiro Imai, Yoji Ishizu, Takashi Honda, Masayo Hama, Tomomi Kataoka, Tomoya Shimokata, Yuichi Ando, Hiroki Kawashima. Outcomes of immune checkpoint inhibitor‐induced liver toxicity managed by hepatologists in a multidisciplinary toxicity team. Hepatology Research 2024; 54(11) doi: 10.1111/hepr.14043
|
| 93 |
Andrew Kynaston, Ken Liu, Alex Davis, Steven Kao, Catriona McKenzie. A case of steroid responsive nivolumab induced cholangitis. Pathology 2022; 54(6) doi: 10.1016/j.pathol.2021.11.009
|
| 94 |
Takafumi Yamano, Masamitsu Hamakawa, Yoko Akaike, Tadashi Ishida. A case report of immune checkpoint inhibitor‐related myositis and cholangitis induced by pembrolizumab. Clinical Case Reports 2024; 12(7) doi: 10.1002/ccr3.9153
|
| 95 |
Shinya Ikeda, Shinya Kawaguchi, Kodai Baba, Haruna Takahashi, Tatsunori Satoh, Shinya Endo, Takafumi Kurokami, Naofumi Shirane, Kazuya Ohno. Salvage tacrolimus therapy for steroid-refractory immune-related adverse event-associated sclerosing cholangitis. Clinical Journal of Gastroenterology 2026; 19(4) doi: 10.1007/s12328-026-02375-4
|
| 96 |
Kohei Okamoto, Susumu Hijioka, Yoshikuni Nagashio, Mao Okada, Akihiro Ohba, Yuta Maruki, Shunsuke Kondo, Chigusa Morizane, Hideki Ueno, Takuji Okusaka. Immune-related adverse event-associated sclerosing cholangitis due to immune checkpoint inhibitors: imaging findings and treatments. Japanese Journal of Clinical Oncology 2024; 54(8) doi: 10.1093/jjco/hyae060
|